About us
Beros Bioderma Technology S.L. (BBT) is a privately owned biotechnology spin-off company originating from research at the University of Córdoba and the Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Spain. Founded to turn scientific discoveries into innovative healthcare products.
With more than a decade of research behind our technology, we bring together expertise in vascular biology, tissue repair, and molecular pharmacology to develop proprietary topical products.
OUR TEAM
BBT was founded by a multidisciplinary team combining academic research, drug development and operational expertise. Together, our founders bring complementary strengths in immunology, molecular pharmacology, preclinical validation and R&D management, supported by international scientific collaborations and a shared commitment to translating research into innovative topical products.
Eduardo Muñoz Blanco, MD, PhD | Scientific Advisor
Professor of Immunology at the University of Córdoba and co-leader of the GC-04 research group at IMIBIC. Inventor of the technology behind BBT-001, he combines expertise in drug discovery and biotechnology entrepreneurship with experience advancing etrinabdione through to Phase II clinical development.
Marco A. Calzado Canale, PhD | Scientific Advisor
Professor of Immunology at the University of Córdoba and leader of the GC-04 research group at IMIBIC. His expertise in intracellular signalling and preclinical drug development supports the mechanistic validation and scientific direction of BBT’s programs.
Laureano de la Vega Martín, PhD | Scientific Advisor
Research group leader at the University of Dundee, UK, specialising in molecular and cell biology. He contributes expertise in advanced cellular models and translational research, strengthening BBT’s international scientific collaborations.
Ana Belén Hidalgo | Administration & Operations
Extensive experience in the financial and operational management of competitive R&D projects. She oversees BBT’s administration, financial management and project coordination.
Francisco J. Ponce Díaz, PhD | Research & Development
Researcher in molecular pharmacology and cell biology, actively involved in developing BBT’s programs. His expertise includes cellular signalling, mechanism-of-action studies and preclinical validation.
Laura Cerero Tejero | Experimental Research
Biochemist with experience in cellular pharmacology and experimental design. She contributes to mechanistic studies and the generation of preclinical evidence supporting BBT’s development programs.